William Blair Has Bearish Estimate for CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Research analysts at William Blair cut their Q1 2025 earnings per share estimates for shares of Charles River Laboratories International in a research report issued to clients and investors on Wednesday, February 19th. William Blair analyst M. Smock now expects that the medical research company will post earnings of $2.06 per share for the quarter, down from their previous forecast of $2.41. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q3 2025 earnings at $2.44 EPS, Q4 2025 earnings at $2.48 EPS, Q4 2026 earnings at $2.68 EPS and FY2026 earnings at $10.33 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the prior year, the business posted $2.46 earnings per share. The business’s revenue was down 1.1% compared to the same quarter last year.

Several other analysts have also recently weighed in on the stock. Barclays decreased their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Morgan Stanley decreased their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 5th. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Evercore ISI lifted their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Finally, UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $195.71.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock opened at $167.10 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $8.54 billion, a price-to-earnings ratio of 1,114.01, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International has a 1-year low of $150.79 and a 1-year high of $275.00. The firm’s 50-day moving average price is $172.00 and its two-hundred day moving average price is $187.54.

Insider Activity at Charles River Laboratories International

In other news, CEO James C. Foster purchased 6,075 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the transaction, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. The trade was a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Charles River Laboratories International

Large investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Charles River Laboratories International by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after purchasing an additional 60,497 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Charles River Laboratories International by 9.0% during the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. State Street Corp boosted its holdings in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after buying an additional 41,421 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Charles River Laboratories International by 2.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after buying an additional 47,221 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock worth $227,042,000 after buying an additional 14,787 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).